KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $7.7 billion.

  • Abbott Laboratories' Cash & Current Investments fell 70.62% to $7.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 billion, marking a year-over-year decrease of 70.62%. This contributed to the annual value of $8.0 billion for FY2024, which is 945.18% up from last year.
  • According to the latest figures from Q3 2025, Abbott Laboratories' Cash & Current Investments is $7.7 billion, which was down 70.62% from $7.3 billion recorded in Q2 2025.
  • Over the past 5 years, Abbott Laboratories' Cash & Current Investments peaked at $10.2 billion during Q4 2021, and registered a low of $6.7 billion during Q1 2024.
  • Its 5-year average for Cash & Current Investments is $8.3 billion, with a median of $8.2 billion in 2023.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 12824.43% in 2021, then crashed by 3022.45% in 2024.
  • Quarter analysis of 5 years shows Abbott Laboratories' Cash & Current Investments stood at $10.2 billion in 2021, then dropped by 0.77% to $10.2 billion in 2022, then decreased by 28.43% to $7.3 billion in 2023, then grew by 9.45% to $8.0 billion in 2024, then decreased by 2.94% to $7.7 billion in 2025.
  • Its last three reported values are $7.7 billion in Q3 2025, $7.3 billion for Q2 2025, and $6.8 billion during Q1 2025.